CO6592108A2 - Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular - Google Patents

Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular

Info

Publication number
CO6592108A2
CO6592108A2 CO12140238A CO12140238A CO6592108A2 CO 6592108 A2 CO6592108 A2 CO 6592108A2 CO 12140238 A CO12140238 A CO 12140238A CO 12140238 A CO12140238 A CO 12140238A CO 6592108 A2 CO6592108 A2 CO 6592108A2
Authority
CO
Colombia
Prior art keywords
intraocular pressure
alpha
long duration
reducing effect
adrenergic agonist
Prior art date
Application number
CO12140238A
Other languages
English (en)
Spanish (es)
Inventor
John E Donello
Daniel W Gil
Mohammed I Dibas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6592108(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO6592108A2 publication Critical patent/CO6592108A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO12140238A 2010-01-21 2012-08-17 Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular CO6592108A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29691210P 2010-01-21 2010-01-21

Publications (1)

Publication Number Publication Date
CO6592108A2 true CO6592108A2 (es) 2013-01-02

Family

ID=44169074

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12140238A CO6592108A2 (es) 2010-01-21 2012-08-17 Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular

Country Status (17)

Country Link
US (1) US9889088B2 (https=)
EP (1) EP2525793B1 (https=)
JP (3) JP2013518051A (https=)
KR (1) KR20120125305A (https=)
CN (1) CN102770135A (https=)
AU (1) AU2011207301A1 (https=)
BR (1) BR112012018154A2 (https=)
CA (1) CA2787573A1 (https=)
CL (1) CL2012002038A1 (https=)
CO (1) CO6592108A2 (https=)
IL (1) IL221030A0 (https=)
MX (1) MX2012008516A (https=)
RU (1) RU2012134065A (https=)
SG (1) SG182637A1 (https=)
TW (1) TW201141477A (https=)
WO (1) WO2011091225A2 (https=)
ZA (1) ZA201205470B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
WO2014159576A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
EP3647420B1 (en) 2017-06-27 2023-08-23 The University Of Tokyo Probe and method for detecting transcript resulting from fusion gene and/or exon skipping
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
PT4236932T (pt) * 2020-11-02 2026-02-23 Visus Therapeutics Inc Composto degradante num medicamento
WO2023086878A1 (en) * 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
EP0775134A4 (en) * 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
US6495583B1 (en) * 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP2009500409A (ja) * 2005-06-29 2009-01-08 アラーガン、インコーポレイテッド 痛みを処置するためのα２アドレナリン作動剤
JP2009525970A (ja) * 2006-02-06 2009-07-16 ニコックス エス エイ α２−アドレナリン受容体アゴニストとしてのアプラクロニジンおよびブリモドニジンのニトロオキシ含有誘導体
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Also Published As

Publication number Publication date
MX2012008516A (es) 2012-10-15
JP2017125074A (ja) 2017-07-20
EP2525793B1 (en) 2018-09-05
US9889088B2 (en) 2018-02-13
ZA201205470B (en) 2013-05-29
RU2012134065A (ru) 2014-02-27
CN102770135A (zh) 2012-11-07
BR112012018154A2 (pt) 2016-04-05
CL2012002038A1 (es) 2012-11-16
AU2011207301A1 (en) 2012-08-09
JP2013518051A (ja) 2013-05-20
SG182637A1 (en) 2012-08-30
IL221030A0 (en) 2012-09-24
CA2787573A1 (en) 2011-07-28
TW201141477A (en) 2011-12-01
JP6466504B2 (ja) 2019-02-06
US20110178145A1 (en) 2011-07-21
WO2011091225A3 (en) 2012-05-18
EP2525793A2 (en) 2012-11-28
JP2016026206A (ja) 2016-02-12
KR20120125305A (ko) 2012-11-14
WO2011091225A2 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
CO6592108A2 (es) Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular
UY32183A (es) Combinacion de una insulina y un agonista de glp-1
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
GT201200217A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
ES2721900T3 (es) Polvo y suspensión acuosa de liberación prolongada que comprende metilfenidato
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
FI20116138A7 (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
NZ706990A (en) A veterinary method of alleviating noise aversion
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
MX376496B (es) Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival.
BR112015026259A2 (pt) combinações de ligantes de adrenoceptor alfa-2 e receptor sigma
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
AR090929A1 (es) Identificacion de la respuesta de un paciente a la administracion del modulador del receptor de s1p

Legal Events

Date Code Title Description
FC Application refused